What Does Unicycive Therapeutics, Inc.'s 39.1% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline
What Does Unicycive Therapeutics, Inc.'s 39.1% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline |
| [22-October-2026] |
Suit alleges Unicycive Therapeutics, Inc. failed to disclose key facts to investors from December 29, 2025 through June 29, 2026; lead plaintiff deadline is November 2, 2026 BENSALEM TOWNSHIP, Pa., Oct. 22, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith today reported that a securities class action lawsuit is pending against Unicycive Therapeutics, Inc. ("Unicycive Therapeutics" or the "Company") (NASDAQ: UNCY) on behalf of investors who acquired its securities from December 29, 2025 through June 29, 2026. The Unicycive Therapeutics, Inc. case, Patel v. Unicycive Therapeutics, Inc., was filed on September 3, 2026 in the U.S. District Court for the Northern District of California (Case No. 26-cv-09559). Investors with losses on Unicycive Therapeutics, Inc. securities can contact the Law Offices of Howard G. Smith about the Unicycive Therapeutics, Inc. lawsuitbefore the November 2, 2026 lead plaintiff deadline. Key deadlines and dates for Unicycive Therapeutics, Inc. investors
What happened? On June 30, 2026, Unicycive Therapeutics disclosed that the FDA had issued a second Complete Response Letter regarding the Company's resubmitted New Drug Application for its kidney disease therapy, oxylanthanum carbonate, identifying the same third-party manufacturing deficiencies that were identified in the previous CRL issued in June 2025. The FDA had not yet inspected the third-party manufacturing facility as part of its review of the resubmission, and raised no concerns about the drug's clinical safety or efficacy. On this news, Unicycive's stock price fell $3.01, or 39.1% (with some reports citing declines up to 46%), to close at $4.69 per share on June 30, 2026, thereby injuring investors. What is the Unicycive Therapeutics, Inc. lawsuit about? The Unicycive Therapeutics, Inc. securities lawsuit alleges that, between December 29, 2025 and June 29, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Unicycive Therapeutics, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) the Company had not inspected its third-party manufacturing vendor's facility or otherwise audited the facility's compliance with current good manufacturing practices; (2) as a result, the Company lacked a reasonable basis to believe that the vendor had resolved the FDA's cited deficiencies; (3) there was an undisclosed risk that the FDA would require additional information about the vendor's facility's manufacturing practices; (4) as a result of the foregoing, the regulatory approval of OLC was reasonably likely to be delayed; and (5) as a result, defendants' positive statements about Unicycive Therapeutics, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. "The lawsuit against Unicycive Therapeutics, Inc. alleges that, among other things, the Company failed to tell investors that the Company had not inspected its third-party manufacturing vendor's facility or otherwise audited the facility's compliance with current good manufacturing practices. Unicycive Therapeutics, Inc. investors who bought during the class period may be able to pursue their losses, and the November 2, 2026 deadline is where that process begins," said Howard G. Smith of The Law Offices of Howard G. Smith. Next steps for Unicycive Therapeutics, Inc. investors Unicycive Therapeutics, Inc. investors who suffered losses may contact The Law Offices of Howard G. Smith to learn about pursuing their claims. Lead plaintiff motions in the Unicycive Therapeutics, Inc. class action are due to the Court by November 2, 2026. For more information, visit the firm's website, email howardsmith@howardsmithlaw.com, or call (215) 638-4847. If you purchased Unicycive Therapeutics, Inc. securities during the class period, you may retain counsel of your choice, or you may take no action and remain an absent class member. No class has been certified in the Unicycive Therapeutics, Inc. case so far. Common questions from Unicycive Therapeutics, Inc. investors Who is eligible? Investors who acquired Unicycive Therapeutics, Inc. securities from December 29, 2025 through June 29, 2026 and suffered losses may qualify for the class in the Unicycive Therapeutics, Inc. shareholder lawsuit. What is the deadline? Lead plaintiff motions in the Unicycive Therapeutics, Inc. case are due by November 2, 2026. Can I recover without being lead plaintiff? Yes, Unicycive Therapeutics, Inc. investors may take no action and remain absent class members. Does it cost anything? The Law Offices of Howard G. Smith works on contingency, so investors pay no attorneys' fees unless there is a recovery, and any fees require court approval. About The Law Offices of Howard G. Smith The Law Offices of Howard G. Smith has helped injured investors recover their money for more than 15 years. The firm prosecutes securities fraud, takeover, and derivative litigation against public companies and their officers, directors, and advisors in federal and state courts nationwide, and has helped clients recover hundreds of millions of dollars in losses. Clients speak directly with a lawyer, who will promptly answer any question. Prior results do not guarantee a similar outcome. Related links
Contact The Law Offices of Howard G. Smith 3070 Bristol Pike, Suite 112 Bensalem, PA 19020 Email: howardsmith@howardsmithlaw.com Telephone: (215) 638-4847 This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. SOURCE Law Offices of Howard G. Smith | ||
Company Codes: NASDAQ:UNCY |
View original content:
